A recent report published by
Infinium Global Research on allergic rhinitis market provides in-depth analysis
of segments and sub-segments in the global as well as regional allergic
rhinitis market. The study also highlights the impact of drivers, restraints,
and macro indicators on the global and regional allergic rhinitis market over
the short term as well as long term. The report is a comprehensive presentation
of trends, forecasts, and dollar values of global allergic rhinitis market.
According to the report, the global allergic rhinitis market is projected to
grow at a CAGR of 3.17% over the forecast period of 2020-2026.
Allergic rhinitis is growing as a
global health problem. Over 400 million people worldwide have allergic
rhinitis, which is largely underdiagnosed and undertreated. In the US, it
affects 10%-30% of the adult population and up to 40% of children. Allergic
rhinitis is treated using medications such as antihistamines, intranasal
corticosteroids, or immunotherapies. Nasonex, Singulair, and Allegra are the
top-selling drugs used for the treatment of allergic rhinitis. Dymista, EpiPen,
and Zyrtec are also used in the treatment of allergic rhinitis. In certain
cases, alternative forms of treatment are also employed. The rising prevalence
of allergic rhinitis worldwide is anticipated to play a major role in the
growth of the market during the forecast period. The allergic Rhinitis Drugs
market is expected to experience stable growth globally. The Allergic Rhinitis
Drugs market accounted for USD 12.88 Billion in 2019 and is expected to reach
USD 15.84 Billion by 2026.
The worldwide prevalence of
allergic rhinitis has witnessed a significant rise, with the regional
prevalence rates varying from 10%-45%. The increasing prevalence could be
attributed to increased exposure to allergens, irritants, and pollutants.
Currently, 40% of children and 10 to 30% of adults are affected by allergic rhinitis.
The European Community Respiratory Health survey recorded a prevalence of 10 to
41% in adults with allergic rhinitis. Furthermore, an increase in exposure to
vehicular pollution, animal dander, or pollen will lead to more people seeking
treatment for the condition, increasing the intake of medicines, contributing
to the growth of the allergic rhinitis drugs market. Additionally, the rise in
awareness about allergic rhinitis due to several government initiatives are
also propelling the growth of the allergic rhinitis drugs market. Besides that,
initiatives by the World Allergy Organization (WAO) Allergic Rhinitis Working
Group have also created awareness about better patient care for individuals
with allergic rhinitis, which in turn is expected to increase the adoption of
allergic rhinitis drugs over the forecast period. However, the side effects of
these drugs are discouraging people from using them though they are effective.
The use of drugs such as azelastine, cetirizine, desloratadine, fexofenadine,
levocetirizine, loratadine, are olopatadine causes nose bleeds, nasal
irritation, watery eyes, itchy nose and throat, insomnia, and dizziness. Apart
from this, some individuals even experience rapid heartbeat, tremors, and
hallucinations. These effects interfere with the daily activities of
individuals, resulting in uncertainty regarding the safety and efficacy of the
drugs. Moreover, the rising investments in R&D to improve the efficiency of
these drugs as well as a large number of pipeline drugs for the treatment of
allergic rhinitis are expected to create fruitful opportunities for the growth
of the allergic rhinitis drugs market.
Furthermore, North America holds
the largest share in the global allergic rhinitis drugs market. The high
awareness about the disease and high spending capacity of the population in
North American countries such as the US and Canada contributes to the growth of
the market in the North America region. Moreover, Europe accounted for the
second-largest share in the global allergic rhinitis drugs market in 2019. The
Asia Pacific has a comparatively low market share as compared to Europe and
North America, but an increase in this share is expected during the forecast
period due to the rise in the incidence of allergic rhinitis. Several studies
suggest that there is an increase in the prevalence of allergic rhinitis in
countries such as China, Japan, and India which will propel growth in this
The report on global allergic
rhinitis market covers segments such as class of drugs, and route of
administration. On the basis of class of drugs, the sub-markets include
immunotherapies, intranasal corticosteroids, and antihistamines. On the basis
of route of administration, the sub-markets include intranasal, oral, and parenteral.
The report provides profiles of
the companies in the market such as GlaxoSmithKline, Merck, Sanofi, Alcon,
Adamis Pharmaceuticals, Belcher Pharmaceuticals, Dr. Reddy's Laboratories,
Mitsubishi Tanabe Pharma, Novartis, and Pfizer.
The report provides deep insights
into the demand forecasts, market trends, and micro and macro indicators. In
addition, this report provides insights into the factors that are driving and
restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis
given in the report brings an insight into the investment areas that existing
or new market players can consider. The report provides insights into the
market using analytical tools such as Porter's five forces analysis and DRO
analysis of allergic rhinitis market. Moreover, the study highlights current
market trends and provides forecast from 2020-2026. We also have highlighted
future trends in the market that will affect the demand during the forecast
period. Moreover, the competitive analysis given in each regional market brings
an insight into the market share of the leading players.